Insmed reports 12-month OLE data for TPIP in pulmonary arterial hypertension
Placebo-crossed patients matched TPIP-continued patients on efficacy measures by month 12, with no newly identified safety signals.
SEC filing
Latest
Thursday, July 16
Jasper Therapeutics completes all-stock merger with Kira Pharmaceuticals, adds $132 million PIPE
The combined company gains Kira's complement and B-cell programs alongside Jasper's briquilimab, with cash expected to last into the second half of 2028.
SEC filing
Quantum Cyber closes purchase of Bridgeport manufacturing facility
The company's subsidiary, Quantum Drones Corporation, finalized acquisition of the 38 Union Avenue property in Bridgeport, Connecticut for $2,300,000 on July 15, 2026.
SEC filing
FDA approves new efficacy supplement for Novartis's Fabhalta
Novartis received priority-review approval for a seventh supplement to Fabhalta's original new drug application, expanding the drug's approved use.
Drugs@FDA
CDT Equity approves 1-for-10 reverse stock split, effective July 17
The Nasdaq bid-price compliance move will cut outstanding shares to roughly 631,077 as trading resumes on a split-adjusted basis July 20.
SEC filing
Jasper Therapeutics completes all-stock merger with Kira Pharmaceuticals
The combined company raised $132 million in a private placement and licensed out two complement assets to Mirador Therapeutics for $12 million upfront.
SEC filing
Inhibrx Biosciences announces $500 million Oxford Finance credit facility, publicly discloses terms
A press release confirms the July 15, 2026 amendment details, including CFO comments tying the funding to two clinical programs awaiting data.
SEC filing
Cardiff Oncology prices $10 million registered direct offering
The clinical-stage biotech will sell shares and warrants at $1.05 apiece, with insiders paying a higher price, closing July 16, 2026.
SEC filing
Adlai Nortye doses first patient in weekly-dosing arm of AN9025 Phase 1 trial
The company said both once-weekly and once-daily dosing arms of its pan-RAS(ON) inhibitor study are now enrolling, with early data expected in 1H27.
SEC filing
Galmed unveils LNP cardiac-targeted Aramchol formulation with Barcode Nanotech
The companies developed a lipid nanoparticle version of Aramchol designed to reach heart tissue instead of the liver, according to a July 16, 2026 filing.
SEC filing
Amgen posts sotorasib trial results, updates Neupogen and Repatha labels; ITP trial recruits
Wednesday, July 15
Veradermics reports positive Phase 2 data for oral VDPHL01 in female hair loss
Study '207' showed hair count gains and high patient-reported improvement rates at Month 6, ahead of a Phase 2/3 readout expected in 1H 2027.
SEC filing
Glucotrack completes business combination with Lōkahi Therapeutics
Lōkahi becomes the operating business of the combined company, with its holders set to own about 90% once preferred stock converts.
SEC filing
GSK completes acquisition of Nuvalent for $10.6 billion
The deal adds three lung cancer assets, including two FDA-reviewed drugs, to GSK's oncology pipeline.
SEC filing
SciSparc's NeuroThera opens German Phase IIb site for Tourette drug SCI-110
NeuroThera Labs added Hannover Medical School as a clinical trial site for its Phase IIb study of SCI-110 in adult Tourette Syndrome patients.
SEC filing
OS Therapies files Form D for debt offering worth up to $9.25 million
The Delaware biotechnology company disclosed a new notice of exempt securities offering to the SEC, with $1.6 million already sold as of the filing date.
SEC filing
Crescent Biopharma prices $117.5 million public offering of shares and warrants
The clinical-stage oncology company set terms for its previously announced offering, expecting net proceeds of about $115.9 million to fund pipeline work into the second half of 2028.
SEC filing (3)
Cullgen discloses 2025 results and merger deal with Gyre Therapeutics
Cullgen's audited 2025 financials, filed with Gyre's SEC report, detail its Astellas collaboration and a March 2026 merger agreement with Gyre.
SEC filing
Jaguar Health files two S-1s to register up to 46.3 million resale shares
The filings, both tied to June 9, 2026 financing deals, cover an equity line of credit and a preferred stock arrangement against just 4.9 million shares outstanding.
SEC filing (2)
AEON Biopharma closes $13.75 million offering with attached milestone warrants
The biosimilar developer priced and closed an underwritten stock and warrant sale, netting $12.2 million with up to $29.6 million more possible if warrants are exercised.
SEC filing (3)
Celldex CFO Sam Martin to retire in March 2027
Celldex Therapeutics disclosed that Chief Financial Officer Sam Martin plans to retire effective on or about March 31, 2027, with a search underway for his successor.
SEC filing
Cadrenal Therapeutics discloses Form D for completed private placement
The company reported gross proceeds of $8,843,849 fully sold in a Regulation D offering that began June 30, 2026, according to a filing signed July 15, 2026.
SEC filing
FDA accepts Axsome's NDA for AXS-12 in narcolepsy cataplexy
The agency set a PDUFA target action date of May 1, 2027 and does not currently plan an advisory committee meeting.
SEC filing
Keros lists Phase 2 trial of KER-065 in Duchenne muscular dystrophy on ClinicalTrials.gov
Cellular Logistics files Form D for $100,000 convertible note offering
The Wisconsin biotechnology company reported $50,000 sold to one investor as of a July 15, 2026 filing.
SEC filing
J&J raises 2026 sales and EPS guidance after strong Q2 results
The company reported second-quarter reported sales of $25.3 billion and lifted its full-year outlook, citing regulatory approvals and pipeline data across Innovative Medicine and MedTech.
SEC filing
Senti Biosciences to spin off SENTI-202 pipeline to Celadon affiliate, retain gene-circuit platform
The July 14, 2026 merger sends most of Senti's business to a private Celadon Partners affiliate while stockholders get CVRs worth up to $60 million tied to SENTI-202 milestones.
SEC filing
Cybin discloses two Form D filings for stock options and RSUs
Cybin Inc. registered separate exempt offerings covering employee stock options and restricted share units, both dated for first sale on July 1, 2026.
SEC filing (2)
Q32 Bio prices public offering, expects about $187.6 million in net proceeds
The company signed an underwriting agreement on July 14, 2026 for shares and pre-funded warrants, with closing expected July 16, 2026.
SEC filing
Q32 Bio prices $200 million stock offering, cites SIGNAL-AA Part B data
The company priced 6,027,399 shares plus pre-funded warrants at $18.25 per share, alongside 36-week topline alopecia areata results from bempikibart.
SEC filing (2)
Vaxcyte board sees director change as Lukatch retires, Markels joins
Heath Lukatch is retiring from Vaxcyte's board effective July 16, 2026, while John Markels joins the same day as a Class II director.
SEC filing
Ensysce Biosciences' chief operating officer resigns effective July 10, 2026
The company disclosed in a filing that Jeffrey Millard stepped down from the COO role, with the resignation taking effect the same day it was submitted.
SEC filing
Pfizer wins four Zithromax label updates in one week; two Phase 2 trial results also posted
Vogenx files for IPO, plans Nasdaq listing under "VOGX"
The clinical-stage metabolic disease company disclosed plans to advance its lead candidate mizagliflozin through mid-stage trials for post-bariatric hypoglycemia and gastroparesis.
SEC filing
ProQR Therapeutics files prospectus for resale of up to 3,030,303 shares
The July 15, 2026 filing covers shares issued in an April 2026 private placement, with expenses borne by ProQR except for the selling shareholder's own counsel and trading costs.
SEC filing
Prestige Brands issues $400 million in senior notes due 2034
The Prestige Consumer Healthcare subsidiary priced 6.250% notes in a private offering, with proceeds terms and redemption rights set out in the indenture.
SEC filing
Ferring wins FDA approval for label update to STIMATE nasal spray
FDA approves subcutaneous Sarclisa Escena with on-body injector for multiple myeloma
Tuesday, July 14
NextCure and Avere Therapeutics agree to all-stock merger, $320 million private placement
Combined company plans to advance oral IL-23 antagonist AVR-001 and trade as Avere Therapeutics under ticker AVRX.
SEC filing
Propanc Biopharma board member departs, accountant Carlo Campiciano appointed to replace her
Annie Van Broekhoven retired from Propanc's board effective July 8, 2026, and the board named Carlo Campiciano to fill the vacancy.
SEC filing
Crescent Biopharma reports about $171.6 million in cash as of June 30, 2026
In an 8-K filing, Crescent Biopharma disclosed preliminary unaudited second-quarter cash figures ahead of its full results.
SEC filing
Silo Pharma closes $4 million private placement priced at-the-market
The Sarasota biopharma entered agreements July 9 and closed the deal July 10, selling shares, pre-funded warrants, and two series of common warrants.
SEC filing (2)
Gérond'if opens REFERENCE-AI trial testing AI echocardiography in geriatric heart failure patients
ARS Pharmaceuticals posts Phase 2 results for intranasal epinephrine ARS-1 in asthma
Gossamer Bio stockholders approve charter amendment, incentive plan changes
At a July 14, 2026 special meeting, shareholders backed a share increase to 4 billion, a restated incentive plan, and authority for a reverse stock split tied to the company's debt exchange.
SEC filing
Erasca prices $550 million stock offering at $17.50 per share
The precision oncology company sold 31,428,572 shares, with underwriters getting an option for millions more, in a deal set to close July 15, 2026.
SEC filing (3)
Cingulate holds annual meeting, restructures board, expands equity plan
Shareholders elected a director, ratified KPMG, and approved a 625,000-share increase to the equity incentive plan at the July 9, 2026 meeting.
SEC filing
TScan Therapeutics registers Phase 3 trial of TSC-101 for AML and MDS transplant patients
Abeona registers long-term safety registry for ZEVASKYN gene therapy in RDEB
Prenetics' IM8 closes $1 billion growth financing from General Catalyst's CVF
Prenetics raised its 2026 IM8 revenue guidance to $210–220 million and said the non-dilutive facility will fund up to 70% of marketing spend.
SEC filing